Adrian Coles

Adrian Coles

Auto-generated profile, based on publicly available information

Adrian Coles

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in JACC
Verified
Journal Article
Closed access
NPNeha J. Pagidipati
Neha J. Pagidipati
KHKshipra Hemal
Kshipra Hemal
ACAdrian Coles
Adrian Coles
DMDaniel B. Mark
Daniel B. Mark
RDRowena J. Dolor
Rowena J. Dolor
PDPamela S. Douglas
Pamela S. Douglas

3 October 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
JPJoseph A. Ladapo, MD, PhD
Joseph A. Ladapo, MD, PhD
UHUdo Hoffmann
Udo Hoffmann
KLKerry L. Lee
Kerry L. Lee
ACAdrian Coles
Adrian Coles
MHMegan Huang
Megan Huang
PDPamela S. Douglas
Pamela S. Douglas
Background: Diagnostic testing in the care of patients newly presenting with symptoms suggestive of coronary artery disease may influence risk factor management, independent of test type or test results. However, little is known about changes in medications and lifestyle after anatomical or functional testing. Methods and Results: We examined what factors influenced preventive medical therapy and lifestyle practices at 60 days among 10 003 symptomatic patients (53% women; mean age 61 years) randomly assigned to anatomical testing with coronary computed tomographic angiography or functional testing (NCT01174550). We also assessed the association of preventive changes with major cardiovascular events. There were no differences in medications/lifestyle at baseline. At 60 days, relative to baseline, the computed tomographic angiography strategy was associated with a higher proportion of patients newly initiating aspirin (11.8% versus 7.8%), statins (12.7% versus 6.2%), and β‐blockers (8.1% versus 5.3%), compared to functional testing ( P <0.0001 for each). No significant differences between computed tomographic angiography and functional testing strategies were observed for initiation of exercise, quitting smoking, or weight loss in overweight/obese patients, though overall prevalence of healthy eating was higher after computed tomographic angiography ( P =0.002) while obese/overweight status was lower ( P =0.040). Positive initial test results and revascularization demonstrated stronger associations with preventive medications and lifestyle than test type. Medication initiation was not associated with fewer cardiovascular events. Conclusions: Positive initial test results and revascularization are primary drivers of changes in preventive medical and lifestyle practices, with test type making secondary contributions. However, substantial opportunities exist to further reduce cardiovascular risk. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01174550.

1 February 2019 in American Heart Journal
Verified
Journal Article
Open access
NPNeha J. Pagidipati
Neha J. Pagidipati
ACAdrian Coles
Adrian Coles
KHKshipra Hemal
Kshipra Hemal
KLKerry L. Lee
Kerry L. Lee
RDRowena J. Dolor
Rowena J. Dolor
PDPamela S. Douglas
Pamela S. Douglas
Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT). We investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Cox regression models assessed the relationship between sex and the composite of all-cause death, myocardial infarction, or unstable angina. Women more often had normal NITs than men (61.0% vs 49.6%, P < .001) and less often had mild (29.3% vs 35.4%, P < .001), moderate (4.0% vs 6.8%, P < .001), or severe abnormalities (5.7% vs 8.3%, P < .001) found on NIT. Women were less likely to be referred for catheterization than men (7.6% vs 12.6%, adjusted OR 0.75 [0.62-0.90]; P = .002). Of those who underwent catheterization within 90 days of randomization (358 women, 534 men), fewer women than men had obstructive coronary artery disease (40.8% vs 60.9%, P < .001). At a 60-day visit, women were significantly less likely than men to report statin use when indicated (adjusted OR 0.81 [0.73-0.91]; P < .001) but were similarly likely to report aspirin use when indicated (adjusted OR 0.78 [0.56-1.08]; P = .13). Over a median follow-up of 25 months, women had better outcomes than men (adjusted OR 0.73 [0.57-0.94]; P = .017). Although women more frequently had normal NITs compared with men, those with abnormalities on NIT were less likely to be referred for catheterization or to receive statin therapy. The high rates of negative NIT in women, coupled with the better outcomes compared with men, strongly support the need for a sex-specific algorithm to guide NIT and chest pain management.

1 February 2017 in American Heart Journal
Verified
Journal Article
Open access
Deepak VooraDeepak Voora
Deepak Voora
ACAdrian Coles
Adrian Coles
KLKerry L. Lee
Kerry L. Lee
UHUdo Hoffmann
Udo Hoffmann
JWJames A. Wingrove
James A. Wingrove
PDPamela S. Douglas
Pamela S. Douglas
Identifying predictors of coronary artery disease (CAD)-related procedures and events remains a priority. We measured an age- and sex-specific gene expression score (ASGES) previously validated to detect obstructive CAD (oCAD) in symptomatic nondiabetic patients in the PROMISE trial. The outcomes were oCAD (≥70% stenosis in ≥1 vessel or ≥50% left main stenosis on CT angiography [CTA]) and a composite endpoint of death, myocardial infarction, revascularization, or unstable angina. The ASGES was determined in 2370 nondiabetic participants (47.5% male, median age 59.5 years, median follow-up 25 months), including 1137 with CTA data. An ASGES >15 was associated with oCAD (odds ratio 2.5 [95% CI 1.6-3.8], P<.001) and the composite endpoint (hazard ratio [HR] 2.6 [95% CI 1.8-3.9], P<.001) in unadjusted analyses. After adjustment for Framingham risk, an ASGES >15 remained associated with the composite endpoint (P=.02); the only component that was associated was revascularization (adjusted HR 2.69 [95% CI 1.52-4.79], P<.001). Compared to noninvasive testing, the ASGES improved prediction for the composite (increase in c-statistic=0.036; continuous net reclassification index=43.2%). Patients with an ASGES ≤15 had a composite endpoint rate no different from those with negative noninvasive test results (3.2% vs. 2.6%, P=.29). A blood-based genomic test for detecting oCAD significantly predicts near-term revascularization procedures, but not non-revascularization events. Larger studies will be needed to clarify the risk with non-revascularization events.

1 November 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
ASAbhinav Sharma
Abhinav Sharma
NSNishant K. Sekaran
Nishant K. Sekaran
ACAdrian Coles
Adrian Coles
NPNeha J. Pagidipati
Neha J. Pagidipati
UHUdo Hoffmann
Udo Hoffmann
PDPamela S. Douglas
Pamela S. Douglas
Background: The impact of diabetes mellitus on the clinical presentation and noninvasive test ( NIT ) results among stable outpatients presenting with symptoms suggestive of coronary artery disease ( CAD ) has not been well described. Methods and Results: The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial enrolled 10 003 patients with known diabetic status, of whom 8966 were tested as randomized and had interpretable NIT results (1908 with diabetes mellitus, 21%). Differences in symptoms and NIT results were evaluated using logistic regression. Patients with diabetes mellitus (versus without) were similar in age (median 61 versus 60 years) and sex (female 54% versus 52%), had a greater burden of cardiovascular comorbidities, and had a similar likelihood of nonchest pain symptoms (29% versus 27%). The Diamond‐Forrester/Coronary Artery Surgery Study score predicted that patients with diabetes mellitus (versus without) had similar likelihood of obstructive CAD (low 1.8% versus 2.7%; intermediate 92.3% versus 92.6%; high 5.9% versus 4.7%). Physicians estimated patients with diabetes mellitus to have a higher likelihood of obstructive CAD (low to very low: 28.3% versus 40.1%; intermediate 63.9% versus 55.9%; high to very high 7.8% versus 4.0%). Patients with diabetes mellitus (versus without) were more likely to have a positive NIT result (15% versus 11%; adjusted odds ratio, 1.23; P =0.01). Conclusions: Stable chest pain patients with and without diabetes mellitus have similar presentation and pretest likelihood of obstructive CAD ; however, physicians perceive that patients with diabetes mellitus have a higher pretest likelihood of obstructive CAD , an assessment supported by increased risk of a positive NIT . Further evaluation of diabetes mellitus's influence on CAD assessment is required. Clinical Trial Registration: URL : https://www.clinicaltrials.gov . Unique identifier: NCT 01174550.

29 July 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
KPKishan S. Parikh
Kishan S. Parikh
ACAdrian Coles
Adrian Coles
PSPhillip J. Schulte
Phillip J. Schulte
WKWilliam E. Kraus
William E. Kraus
JFJerome L. Fleg
Jerome L. Fleg
RMRobert J. Mentz
Robert J. Mentz